This study is looking into a new approach for Frontotemporal Degeneration (FTD), a condition affecting brain function. Researchers believe that inflammation in the brain plays a role in FTD. They are testing if a combination of two drugs, abatacept and aldesleukin (a low dose of interleukin-2 or IL-2), can help by improving the body's immune response. Specifically, they hope these drugs can restore certain immune cells called regulatory T cells (Tregs) that may not be working well in FTD patients. The main goal of this study is to see if this treatment is safe and well-tolerated over a 6-month period. They plan to enroll about 10 participants between 18 and 86 years old who have been diagnosed with probable FTD. If you are on medications that affect thinking or behavior, you must be on a stable dose for at least 4 weeks before starting and throughout the study.

Study design

This is an interventional study with a planned enrollment of 10 participants. The phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for safety and tolerability is measured at the 6-month treatment phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.